Introduction

Co-infection with hepatitis C virus (HCV) is common in human immunodeficiency virus (HIV)-
infected patients as the viruses share routes of transmission. Co-infected patients have higher HCV loads and faster progression to liver disease. Antiretroviral therapy (ART) has improved life expectancy, so more cases of HCV-associated liver disease arise. Beneficial effects of ART may not be as great in co-infected patients [1, 2] , but HCV-specific cell-mediated immune responses are restored [3, 4] . In some patients, this coincided with elevated serum alanine aminotransferase (ALT) levels [5] [6] [7] [8] in a phenomenon known as immune restoration disease (IRD) [6, 8] . Longitudinal studies of antibody responses in HIV/HCV patients receiving ART are limited. In a three year study, HIV/HCV patients were unable to normalise circulating B-cell counts or serum total IgG levels [9] . Titres of HCV-reactive antibodies increased after 1 year of ART, with no changes in HCV viral loads [10] .
The establishment of a cell-culture system for HCV has allowed evaluation of antibodies that can neutralise HCV infection. Neutralising antibody (nAb) can be detected using the HCV genotype 2a strain, JFH-1, in HCV mono-infected patients chronically infected with different HCV genotype [11, 12] . HIV co-infection reduced nAb levels in a cross-sectional study [13] , but we have found no longitudinal data examining HIV/HCV patients after starting ART. We present an extended analysis of HCV antibody responses detected using JFH-1, and recombinant core and non-structural antigens. Changes observed on ART are analysed in individual patients to dissect out causes and consequences of perturbations in the HCV viral loads and CD4 + T-cell counts.
Materials and Methods
Patients and controls
genotype was determined by RT-PCR with a melting curve analysis using FRET probes [16] .
HCV mono-infected patients were genotyped using LiPA Kits (Inno-Lipa, Innogenetics, Ghent, Belgium).
Total IgG and CMV antibody ELISAs
Plates were coated overnight with 5µg/mL polyvalent goat antihuman immunoglobulin (Invitrogen), washed with 0.05% Tween/PBS and blocked with 5% BSA/PBS. Plates were washed again and plasma/serum serially diluted in 2% BSA/PBS was added. Human IgG (0.5ug/mL, Sigma, Castle Hill, NSW, Australia) was diluted in 2% BSA/PBS as a standard.
Bound Ig was detected with horseradish peroxidase conjugated anti-human IgG (Jackson Immunoresearch, West Grove, PA), followed by tetramethylbenzidine substrate (Sigma).
Reactions were stopped with 1M H2SO4 and absorbance measured at 450nm. The coefficient of variance for the assay was 11%.
To assess CMV-reactive antibody, plates were coated with a lysate of human foreskin fibroblasts infected with CMV AD169 as previously described [17] . The coefficient of variance was 13%.
HCV antibody ELISAs
Production of HCV (JFH-1) in human hepatoma HuH-7 cells has been previously described [18] .
JFH-1 infected cells were resuspended in buffer containing protease inhibitors and subjected to decompression lysis. Lysates from the same number of uninfected HuH-7 cells were prepared as a negative control. Microtitre plates were coated with HuH-7 lysates, or 0.5µg/mL recombinant HCV core (genotype 1b), NS3 (genotype 1b), NS4 (genotype 1 a) or NS5 antigens (MyBioSource, San Diego, CA). Plasma from an individual positive using AxSYM HCV HIV/HCV patients were significantly younger and had lower serum ALT levels and CD4 + T-cell counts than HCV mono-infected patients. Seven HIV/HCV patients (P1, P2, P7, P10, P11, P12, P17) started ART with CD4 + T-cell counts below 50 cells/L.
Statistical analyses spanned 520 weeks, with most patients followed to this timepoint. Median (range) CD4 + T-cell counts increased from 150 (14-149) to 400 (200-1274) cells/L at 520 weeks (Supplementary Figure 1a) , with a significant increase at 104 weeks (p=0.05) and smaller increments thereafter. Eight patients (P1, P2, P7, P10, P11, P12, P15, P17) achieved more than a 4-fold increase in CD4 + T-cell counts. CD4 + T-cell counts remained below 200 cells/L in
P17.
Median serum ALT levels increased from 41 (15-86) to 81 (29-663) U/mL at week 52 (p=0.006) (Supplementary Figure 1b) , and were elevated above baseline at 104 (p=0.07), 208 (p=0.01), 312 (p=0.06) and 416 (p=0.006) weeks. Ten patients experienced a >3-fold rise in serum ALT to over 100 U/mL on ART (P1, P3, P4, P6, P9, P10, P11, P13, P16, P17).
Persistent suppression of HIV replication (defined as less than one rebound in HIV viremia >3.0 log10) on ART was achieved in P1, P2, P7, P8, P10, P12, P14 and P15.
Low JFH-1 antibody responses did not reflect a global defect in antibody responses
Levels of total IgG were higher in HIV/HCV patients prior to starting ART than HCV monoinfected patients (p=0.0003) and controls (p=0.006) (Figure 1a ). Amongst the individuals who were CMV seropositive (15 HIV/HCV patients, 10 HCV patients and 12 controls), CMV antibody levels were higher in HIV/HCV patients than mono-infected patients (p=0.01) and controls (p=0.003) (Figure 1b ). CMV antibody levels were similar in mono-infected patients and controls.
As this does not suggest a global defect in antibody responses, it is striking that HIV/HCV patients had lower levels of antibody reactive to JFH-1 and genotype cross-reactive nAb50 titres than HCV mono-infected patients (p<0.0001), although levels were higher than in controls (p<0.0001) (Figures 1c and 1h) . P1, P5, P6, P9, P11, P12, P15, P16 and P17 had undetectable or low nAb50 titres. HCV core antibody levels were also lower in HIV/HCV patients than HCV mono-infected patients (p=0.0002), but higher than controls (p<0.0001) (Figure 1d ).
In contrast, levels of antibody to NS3 and NS5 antigens were higher in HIV/HCV patients than HCV mono-infected patients (p<0.0001) (Figures 1e and 1g ). NS4 antibody levels were similar in both patient groups (p=0.41) and higher than controls (p<0.0001) (Figure 1f ). 
Levels of JFH
Co-infected patients retained elevated levels of total IgG and antibody to CMV on ART
Twelve of the 17 HIV/HCV patients had total IgG levels above mono-infected patients and controls in at least 1 follow-up sample (Figure 2a ). For example, P2 began ART with high levels that normalised after 104 weeks, whilst P9 started with normal levels which rose and only normalised after 465 weeks. Only P14 retained low levels over 718 weeks of follow-up. CMVreactive antibody rose during the first year of ART and remained highest in co-infected patients ( Figure 2b ). However, P3 and P14 were CMV seronegative at baseline and did not seroconvert, and CMV antibody levels declined in P1, P2, P10 and P11.
JFH-1 reactive antibody responses increased on ART, irrespective of baseline CD4 + Tcell counts or changes in serum ALT levels during therapy
With the exception of P11, JFH-1 reactive antibody levels increased in most patients within 52 weeks on ART ( Figure 2c ) coincident with a rise in genotype cross-reactive nAb50 titres ( Figure   2d ). For P1, P5 and P16, the rise in nAb50 titres was delayed (210, 257 and 91 weeks, respectively). After 205 (186-225) weeks, co-infected patients attained nAb50 titres similar to mono-infected patients, whereas levels of JFH-1 antibody remained lower than in mono-infected patients. HCV core antibody levels were significantly lower than mono-infected patients at baseline and during the first few years of ART, but normalised after 258 (242-270) weeks (Supplementary Figure 2a) . HCV NS3 and NS5 antibody levels also began low and normalised after 522 (504-538) weeks ( Supplementary Figures 2b & d) , whereas NS4 antibody levels were stable on ART and similar to mono-infected patients (Supplementary Figure 2c) . Figure 3b) . In contrast, JFH-1 reactive antibody levels increased significantly by week 52 in both patient groups (Supplementary Figure 3a) . There were no statistical differences in antibody responses between patients stratified by serum ALT levels (data not shown).
JFH-1 antibody responses reflect HCV viral loads during ART
Longitudinal samples identified three patterns associating JFH-1 antibody responses with HCV viral loads during ART. Informative examples are shown in Figure 3 .
The first pattern was elevated HCV viral loads despite the development of antibody responses.
P8 and P13 ( Figure 3a) were followed for 637 and 597 weeks, respectively, with two treatment interruptions triggering a rebound in HIV viremia and a decrease in CD4 + T-cell count. JFH-1 antibody levels increased within the first year of ART and declined when ART was interrupted.
HCV viral loads increased after weeks 144 and 22 (P8 and P13, respectively) and remained elevated. The rise was accompanied by an increase in nAb50 titres. Similar antibody profiles were seen for patients P4, P5, P9, P14 and P16 (data not shown).
The second pattern was an inverse relationship between antibody responses and HCV viral loads which was seen for patients P1, P3, P6, P7, P10, P12, P15 and P17. For example; P12 ( Figure   3b ) achieved an immunological and virological response during ART and had no treatment interruptions. Levels of antibody reactive to JFH-1 and nAb50 titres were low at the start of ART but increased during follow-up, correlating with control of HCV viral replication. A rebound in HIV viremia at week 278 for P12 was associated with decreased CD4 + T-cell count, reduced JFH-1 antibody response and increased HCV viral load. For P7 (Figure 3b) A mixed pattern was demonstrated in P2 who started ART with <50 CD4 + T-cell counts/L and achieved an immunological and virological response to ART (Figure 3c ). JFH-1 antibody levels and nAb50 titres were low at week 4, but increased at 104 weeks with a concomitant rise in HCV viral load. Suppression of viral replication at week 152 paralleled a reduction in JFH-1 antibody and a HCV viral rebound at week 256 corresponded with an increase in JFH-1 antibody and nAb50 titres. However, failure to maintain nAb responses after 474 weeks was linked to a dramatic rise in HCV RNA levels, so the antibody profile changed from pattern 1 to pattern 2.
Antibodies to JFH-1 declined on HCV therapy but antibodies to non-structural proteins increased with control of HCV replication
Four patients received anti-HCV therapy. P1, P10 and P14 were treated with IFNα/ribavirin for 48 weeks and achieved a sustained virological response, followed by lower JFH-1 antibody and nAb50 titres (Figures 4a, b & c) . HCV core antibody levels also declined in patients with sustained virological response (data not shown). It is noteworthy that P10 was able to control HCV replication despite having low nAb50 titres compared to other patients. This may be due to the fact that this patient was infected with the genotype 2 strain of HCV which is the same as the and P13 (not shown)).
Discussion
We present a comprehensive analysis of HCV-specific antibody responses in HIV/HCV coinfected patients followed for 11 years after initiating ART. We used antigens from cell cultures infected with the HCV genotype 2a virus, JFH-1, and commercially available recombinant proteins from HCV genotype 1. An advantage of using JFH-1 is the inclusion of envelope proteins (E1 or E2). We show that patterns of antibody responses differ with the antigen. Levels of JFH-1 and HCV core reactive antibodies were lower in untreated HIV/HCV patients than in HCV mono-infected patients. In contrast, levels of NS3 and NS5 antibody were high and NS4
antibodies were similar to HCV mono-infected patients.
Core is highly immunogenic, being recognized by 97% of patients with chronic HCV infection [19, 20] . In addition, levels of antibodies to core can be 10-fold higher than those reported for E2, NS3, NS4 and NS5 [21] . Thus the lower JFH-1 antibody levels observed in HIV/HCV patients may reflect reduced levels of antibody to core, despite the high antibody levels to NS3 and NS5. Our findings differ from a report of weak reactivity to NS3, NS4 and NS5 Here, genotype cross-reactive nAb50 titres were lower in untreated co-infected patients compared to HCV mono-infected patients, with undetectable or low titres of nAb in nine co-infected individuals. These patients may have antibodies that do not cross-neutralise with JFH-1.
Baseline JFH-1 antibody levels correlated with CD4 + T-cell counts in HIV/HCV patients.
Accordingly, antibodies to HCV core, NS3, NS4 and NS5 antigens were lowest in untreated HIV/HCV patients with CD4 + T-cell counts below 200 cells/L [32] . Here, antibody responses increased on ART, but only nAb50 titres reached levels seen in HCV mono-infected patients. We also demonstrated a significant increase in JFH-1 antibody levels and nAb50 titres in longitudinal samples from Indonesian HIV/HCV patients after 1 year of ART [18] . In a cross-sectional study of HIV/HCV patients who had controlled HIV viremia during ART, nAb50 titres were significantly lower than HCV mono-infected patients [13] , but the duration of treatment was not specified. Here, nAb50 titres were significantly lower than HCV mono-infected patients during the first 4 years but normalised with longer periods of ART ( Figure 2 ).
Recovery of antibody responses on ART was also evident with CMV, and may reflect restored T-cell help for B-cell responses as it paralleled improved HCV-specific CD4 + and CD8 + T-cell responses [3, 4] . This trend over time was evident in our study, but increases in JFH-1 antibody responses on ART were independent of CD4 + T-cell counts at recruitment. In contrast, cell- Liver enzyme levels increase in some HIV/HCV co-infected patients beginning ART [5] [6] [7] [8] is represented by grey shaded areas. HIV viral loads were considered detectable (+) if above 3.0 log10 copies/mL. JFH-1 antibody levels were as described in Figure 3 . The 50% neutralising antibody (nAb50) titre was the plasma dilution required to inhibit JFH-1 infection by 50%. HIV viral loads were considered detectable (+) if above 3.0 log10 copies/mL. JFH-1 antibody levels were as described in Figure 3 . The 50% neutralising antibody (nAb50) titre was the plasma dilution required to inhibit JFH-1 infection by 50%. 
